NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $44,894 | +26782.6% | 63,869 | -13.6% | 0.00% | -100.0% |
| Q4 2022 | $167 | -29.5% | 73,911 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $237 | -99.9% | 73,911 | +4.8% | 0.00% | 0.0% |
| Q2 2022 | $268,000 | -29.5% | 70,528 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $380,000 | -86.6% | 70,528 | -66.4% | 0.00% | -90.0% |
| Q4 2021 | $2,835,000 | +10.1% | 209,840 | +39.9% | 0.01% | 0.0% |
| Q2 2021 | $2,574,000 | -14.2% | 150,000 | 0.0% | 0.01% | -16.7% |
| Q1 2021 | $3,000,000 | -7.0% | 150,000 | +7.7% | 0.01% | -25.0% |
| Q2 2020 | $3,225,000 | +21.0% | 139,269 | -6.7% | 0.02% | +6.7% |
| Q1 2020 | $2,665,000 | +236.5% | 149,285 | +243.2% | 0.02% | +275.0% |
| Q3 2019 | $792,000 | -44.6% | 43,498 | +8.3% | 0.00% | -42.9% |
| Q2 2019 | $1,429,000 | -2.4% | 40,166 | -7.8% | 0.01% | 0.0% |
| Q1 2019 | $1,464,000 | -0.7% | 43,564 | -2.9% | 0.01% | -12.5% |
| Q4 2018 | $1,474,000 | -58.0% | 44,853 | -22.1% | 0.01% | -52.9% |
| Q3 2018 | $3,511,000 | +88.3% | 57,597 | +50.8% | 0.02% | +88.9% |
| Q2 2018 | $1,865,000 | -67.0% | 38,191 | -28.3% | 0.01% | -69.0% |
| Q1 2018 | $5,657,000 | -22.9% | 53,234 | -56.7% | 0.03% | -12.1% |
| Q4 2017 | $7,341,000 | +126.4% | 122,920 | -9.0% | 0.03% | +106.2% |
| Q3 2017 | $3,243,000 | +15.5% | 135,105 | -5.9% | 0.02% | +23.1% |
| Q2 2017 | $2,808,000 | -16.7% | 143,644 | 0.0% | 0.01% | -18.8% |
| Q1 2017 | $3,371,000 | +129.8% | 143,644 | +20.2% | 0.02% | +100.0% |
| Q4 2016 | $1,467,000 | -21.3% | 119,521 | +10.1% | 0.01% | -11.1% |
| Q3 2016 | $1,865,000 | +20.7% | 108,576 | 0.0% | 0.01% | +12.5% |
| Q2 2016 | $1,545,000 | +6.6% | 108,576 | +2.9% | 0.01% | 0.0% |
| Q1 2016 | $1,450,000 | -16.5% | 105,486 | +2.4% | 0.01% | -20.0% |
| Q4 2015 | $1,736,000 | +34.7% | 103,000 | 0.0% | 0.01% | +42.9% |
| Q2 2015 | $1,289,000 | – | 103,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |